Depersonalization can consist of a detachment within the self, regarding one's mind or body, or being a detached observer of oneself. Subjects feel they have changed and that the world has become vague, dreamlike, less real, lacking in significance or being outside reality while looking in. It can be described as feeling like one is on “autopilot” and that the person's sense of individuality or selfhood has been hindered or suppressed.
Chronic depersonalization refers to depersonalization/derealization disorder, which is classified by the DSM-5 as a dissociative disorder, based on the findings that depersonalization and derealization are prevalent in other dissociative disorders including dissociative identity disorder.
Though degrees of depersonalization and derealization can happen to anyone who is subject to temporary anxiety or stress, chronic depersonalization is more related to individuals who have experienced a severe trauma or prolonged stress/anxiety. Depersonalization-derealization is the single most important symptom in the spectrum of dissociative disorders, including dissociative identity disorder and "dissociative disorder not otherwise specified" (DD-NOS). It is also a prominent symptom in some other non-dissociative disorders, such as anxiety disorders, clinical depression, bipolar disorder, schizophrenia, schizoid personality disorder, hypothyroidism or endocrine disorders, schizotypal personality disorder, borderline personality disorder, obsessive–compulsive disorder, migraines, and sleep deprivation; it can also be a symptom of some types of neurological seizure.
In social psychology, and in particular self-categorization theory, the term depersonalization has a different meaning and refers to "the stereotypical perception of the self as an example of some defining social category".
Individuals who experience depersonalization feel divorced from their own personal self by sensing their body sensations, feelings, emotions, behaviors, etc. as not belonging to the same person or identity. Often a person who has experienced depersonalization claims that things seem unreal or hazy. Also, a recognition of a self breaks down (hence the name). Depersonalization can result in very high anxiety levels, which further increase these perceptions.
Depersonalization is a subjective experience of unreality in one's self, while derealization is unreality of the outside world. Although most authors currently regard depersonalization (personal/self) and derealization (reality/surroundings) as independent constructs, many do not want to separate derealization from depersonalization.
Depersonalization is a symptom of anxiety disorders, such as panic disorder. It can also accompany sleep deprivation (often occurring when experiencing jet lag), migraine, epilepsy (especially temporal lobe epilepsy,complex-partial seizure, both as part of the aura and during the seizure), obsessive-compulsive disorder, severe stress or trauma, anxiety, the use of recreational drugs —especially cannabis, hallucinogens, ketamine, and MDMA, certain types of meditation, deep hypnosis, extended mirror or crystal gazing, sensory deprivation, and mild-to-moderate head injury with little or full loss of consciousness (less likely if unconscious for more than 30 minutes). Interoceptive exposure is a non-pharmacological method that can be used to induce depersonalization.
In the general population, transient depersonalization/derealization are common, having a lifetime prevalence between 26 and 74%. A random community-based survey of 1,000 adults in the US rural south found a 1-year depersonalization prevalence rate at 19%. Several studies, but not all, found age to be a significant factor: adolescents and young adults in the normal population reported the highest rate. In a study, 46% of college students reported at least one significant episode in the previous year. In another study, 20% of patients with minor head injury experience significant depersonalization and derealization. Several studies found that up to 66% of individuals in life-threatening accidents report transient depersonalization at minimum during or immediately after the accidents.
Depersonalization occurs 2-4 times more in women than in men.
A similar and overlapping concept called ipseity disturbance (ipse is Latin for "self" or "itself") may be part of the core process of schizophrenia spectrum disorders. However, specific to the schizophrenia spectrum seems to be "a dislocation of first-person perspective such that self and other or self and world may seem to be non-distinguishable, or in which the individual self or field of consciousness takes on an inordinate significance in relation to the objective or intersubjective world" (emphasis in original).
For the purposes of evaluation and measurement depersonalization can be conceived of as a construct and scales are now available to map its dimensions in time and space.[clarification needed] A study of undergraduate students found that individuals high on the depersonalization/derealization subscale of the Dissociative Experiences Scale exhibited a more pronounced cortisol response in stress. Individuals high on the absorption subscale, which measures a subject's experiences of concentration to the exclusion of awareness of other events, showed weaker cortisol responses.
In general infantry and special forces soldiers, measures of depersonalization and derealization increased significantly after training that includes experiences of uncontrollable stress, semi-starvation, sleep deprivation, as well as lack of control over hygiene, movement, communications, and social interactions.
Pharmacological and situational causesEdit
Depersonalization has been described by some as a desirable state, particularly by those that have experienced it under the influence of mood-altering recreational drugs. It is an effect of dissociatives and psychedelics, as well as a possible side effect of caffeine, alcohol, amphetamine, cannabis, and antidepressants. It is a classic withdrawal symptom from many drugs.
Benzodiazepine dependence, which can occur with long-term use of benzodiazepines, can induce chronic depersonalization symptomatology and perceptual disturbances in some people, even in those who are taking a stable daily dosage, and it can also become a protracted feature of the benzodiazepine withdrawal syndrome.
Lieutenant Colonel Dave Grossman, in his book On Killing, suggests that military training artificially creates depersonalization in soldiers, suppressing empathy and making it easier for them to kill other human beings.
Graham Reed (1974) claimed that depersonalization occurs in relation to the experience of falling in love.
Depersonalization as a psychobiological mechanismEdit
Depersonalization is a classic response to acute trauma, and may be highly prevalent in individuals involved in different traumatic situations including motor vehicle accident, and imprisonment.
Psychologically depersonalization can, just like dissociation in general, be considered a type of coping mechanism. Depersonalization is in that case unconsciously used to decrease the intensity of unpleasant experience, whether that is something as mild as stress or something as severe as chronically high anxiety and post-traumatic stress disorder.
The decrease in anxiety and psychobiological hyperarousal helps preserving adaptive behaviors and resources under threat or danger.
Depersonalization is an overgeneralized reaction in that it doesn't diminish just the unpleasant experience, but more or less all experience – leading to a feeling of being detached from the world and experiencing it in a more bland way. An important distinction must be made between depersonalization as a mild, short-term reaction to unpleasant experience and depersonalization as a chronic symptom stemming from a severe mental disorder such as PTSD or dissociative identity disorder.
Chronic symptoms may represent persistence of depersonalization beyond the situations under threat.
Treatment is dependent on the underlying cause, whether it is organic or psychological in origin. If depersonalization is a symptom of neurological disease, then diagnosis and treatment of the specific disease is the first approach. Depersonalization can be a cognitive symptom of such diseases as amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis (MS), or any other neurological disease affecting the brain. For those with both depersonalization and migraine, tricyclic antidepressants are often prescribed.
If depersonalization is a symptom of psychological causes such as developmental trauma, treatment depends on the diagnosis. In case of dissociative identity disorder or DD-NOS as a developmental disorder, in which extreme developmental trauma interferes with formation of a single cohesive identity, treatment requires proper psychotherapy, and—in the case of additional (co-morbid) disorders such as eating disorders—a team of specialists treating such an individual. It can also be a symptom of borderline personality disorder, which can be treated in the long term with proper psychotherapy and psychopharmacology.
The treatment of chronic depersonalization is considered in depersonalization disorder.
A 2001 Russian study showed that naloxone, a drug used to reverse the intoxicating effects of opioid drugs, can successfully treat depersonalization disorder. According to the study: "In three of 14 patients, depersonalization symptoms disappeared entirely and seven patients showed a marked improvement. The therapeutic effect of naloxone provides evidence for the role of the endogenous opioid system in the pathogenesis of depersonalization." The anti convulsion drug Lamotrigine has shown some success in treating symptoms of depersonalization, often in combination with a selective serotonin reuptake inhibitor and is the first drug of choice at the depersonalisation research unit at King's College London.
The Depersonalisation Research Unit at the Institute of Psychiatry in London conducts research into depersonalization disorder. Researchers there use the acronym DPAFU (Depersonalisation and Feelings of Unreality) as a shortened label for the disorder.
In a 2020 article in the Journal Nature, Vesuna, et al. describe experimental findings which show that layer 5 of the retrosplenial cortex is likely responsible for dissociative states of consciousness in mammals.
Studies suggest transgender individuals who have not undergone gender transition experience higher rates of depersonalization and other dissociative symptoms than cisgender individuals. Transgender people who have undergone medical gender transition, such as hormone replacement therapy, have often been found to experience lessened symptoms of depersonalization.
- Brain fog
- Catatonic state
- Dissociation (psychology)
- Ego death
- Falling (sensation)
- Hallucinogen persisting perception disorder
- Human spirit
- Nina Searl
- Out-of-body experience
- Post-traumatic stress disorder
- Psychedelic experience
- Psychological trauma
- Spiritual crisis
- ^ Sierra, M.; Berrios, G. E. (2001). "The phenomenological stability of depersonalization: Comparing the old with the new". The Journal of Nervous and Mental Disease. 189 (9): 629–36. doi:10.1097/00005053-200109000-00010. PMID 11580008. S2CID 22920376.
- ^ "Depersonalization-derealization disorder - Symptoms and causes". Mayo Clinic. Retrieved 2022-03-28.
- ^ American Psychiatry Association (2013). "Dissociative Disorders". Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington: American Psychiatric Publishing. pp. 291-307. ISBN 978-0-89042-555-8.
- ^ a b c d Dissociative Disorders (2017), CHANGES IN DIAGNOSTIC CRITERIA TO THE DISSOCIATIVE DISORDERS, Changes to the Diagnostic Criteria for Depersonalization Disorder
- ^ a b Sass, Louis; Pienkos, Elizabeth; Nelson, Barnaby; Medford, Nick (2013). "Anomalous self-experience in depersonalization and schizophrenia: A comparative investigation". Consciousness and Cognition. 22 (2): 430–441. doi:10.1016/j.concog.2013.01.009. PMID 23454432. S2CID 13551169.
- ^ a b Sharma, Kirti; Behera, Joshil Kumar; Sood, Sushma; Rajput, Rajesh; Satpal; Praveen, Prashant (2014). "Study of cognitive functions in newly diagnosed cases of subclinical and clinical hypothyroidism". Journal of Natural Science, Biology, and Medicine. 5 (1): 63–66. doi:10.4103/0976-9668.127290. ISSN 0976-9668. PMC 3961955. PMID 24678200.
- ^ Turner, John; Oakes, Penny (1986). "The significance of the social identity concept for social psychology with reference to individualism, interactionism and social influence". British Journal of Social Psychology. 25 (3): 237–52. doi:10.1111/j.2044-8309.1986.tb00732.x.
- ^ Depersonalization Disorder at Merck Manual of Diagnosis and Therapy Home Edition[permanent dead link]
- ^ Hall-Flavin, Daniel. "Depersonalization disorder: A feeling of being 'outside' your body". Retrieved 2007-09-08.
- ^ Radovic, F.; Radovic, S. (2002). "Feelings of Unreality: A Conceptual and Phenomenological Analysis of the Language of Depersonalization". Philosophy, Psychiatry, & Psychology. 9 (3): 271–9. doi:10.1353/ppp.2003.0048. S2CID 145074433.
- ^ Sierra-Siegert M, David AS (December 2007). "Depersonalization and individualism: the effect of culture on symptom profiles in panic disorder". Journal of Nervous and Mental Disease. 195 (12): 989–95. doi:10.1097/NMD.0b013e31815c19f7. PMID 18091192. S2CID 7182322.
- ^ Simeon D (2004). "Depersonalisation Disorder: A Contemporary Overview". CNS Drugs. 18 (6): 343–54. doi:10.2165/00023210-200418060-00002. PMID 15089102. S2CID 18506672.
- ^ Michelle V. Lambert; Mauricio Sierra; Mary L. Phillips; Anthony S. David (May 2002). "The Spectrum of Organic Depersonalization: A Review Plus Four New Cases". The Journal of Neuropsychiatry and Clinical Neurosciences. 14 (2): 141–54. doi:10.1176/appi.neuropsych.14.2.141. PMID 11983788.
- ^ a b c Dissociative Disorders (2017), GENERAL POPULATION STUDIES OF DISSOCIATIVE DISORDERS, Epidemiology of Depersonalization and Derealization Symptoms.
- ^ "Depersonalization-derealization disorder - Symptoms and causes". Mayo Clinic. Retrieved 2019-11-20.
- ^ Lickel J; Nelson E; Lickel A H; Brett Deacon (2008). "Interoceptive Exposure Exercises for Evoking Depersonalization and Derealization: A Pilot Study". Journal of Cognitive Psychotherapy. 22 (4): 321–30. doi:10.1891/0889-83220.127.116.111. S2CID 12746427.
- ^ Sadock, BJ; Sadock, VA (2015). "12: Dissociative Disorders". Kaplan and Sadock's Synopsis of Psychiatry (11th ed.). Wolters Kluwer. DEPERSONALIZATION/DEREALIZATION DISORDER, Epidemiology, pp. 454-455. ISBN 978-1-60913-971-1.
- ^ Sass, Louis A.; Parnas, Josef (2003). "Schizophrenia, Consciousness, and the Self". Schizophrenia Bulletin. 29 (3): 427–44. doi:10.1093/oxfordjournals.schbul.a007017. PMID 14609238.
- ^ Sierra, Mauricio; Berrios, German E. (2000). "The Cambridge Depersonalisation Scale: A new instrument for the measurement of depersonalisation". Psychiatry Research. 93 (2): 153–164. doi:10.1016/S0165-1781(00)00100-1. PMID 10725532. S2CID 206024895.
- ^ Giesbrecht, T.; T. Smeets; H. Merckelbac; M. Jelicic (2007). "Depersonalization experiences in undergraduates are related to heightened stress cortisol responses". Journal of Nervous and Mental Disease. 195 (4): 282–87. doi:10.1097/01.nmd.0000253822.60618.60. PMID 17435477. S2CID 9283387.
- ^ Stein, M. B.; Uhde, TW (July 1989). "Depersonalization Disorder: Effects of Caffeine and Response to Pharmacotherapy". Biological Psychiatry. 26 (3): 315–20. doi:10.1016/0006-3223(89)90044-9. PMID 2742946. S2CID 34396397.
- ^ Raimo, E. B.; R. A. Roemer; M. Moster; Y. Shan (June 1999). "Alcohol-Induced Depersonalization". Biological Psychiatry. 45 (11): 1523–6. doi:10.1016/S0006-3223(98)00257-1. PMID 10356638. S2CID 34049706.
- ^ Cohen, P. R. (2004). "Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline". Southern Medical Journal. 97 (1): 70–73. doi:10.1097/01.SMJ.0000083857.98870.98. PMID 14746427. S2CID 27125601.
- ^ "Medication-Associated Depersonalization Symptoms". medscape.com.
- ^ Arehart-Treichel, Joan (2003-08-15). "Depersonalization Again Finds Psychiatric Spotlight". Psychiatric News. 38 (16): 18–30. doi:10.1176/pn.38.16.0018.
- ^ Marriott, S.; P. Tyrer (1993). "Benzodiazepine dependence: avoidance and withdrawal". Drug Safety. 9 (2): 93–103. doi:10.2165/00002018-199309020-00003. PMID 8104417. S2CID 8550990.
- ^ Shufman, E.; A. Lerner; E. Witztum (2005). "Depersonalization after withdrawal from cannabis usage" [Depersonalization after withdrawal from cannabis usage]. Harefuah (in Hebrew). 144 (4): 249–51 and 303. PMID 15889607.
- ^ Djenderedjian, A.; R. Tashjian (1982). "Agoraphobia following amphetamine withdrawal". The Journal of Clinical Psychiatry. 43 (6): 248–49. PMID 7085580.
- ^ Mourad, I.; M. Lejoyeux; J. Adès (1998). "Evaluation prospective du sevrage des antidépresseurs" [Prospective evaluation of antidepressant discontinuation]. L'Encéphale (in French). 24 (3): 215–22. PMID 9696914.
- ^ Ashton, Heather (1991). "Protracted withdrawal syndromes from benzodiazepines". Journal of Substance Abuse Treatment. 8 (1–2): 19–28. doi:10.1016/0740-5472(91)90023-4. PMID 1675688.
- ^ Terao T; Yoshimura R; Terao M; Abe K (1992-01-15). "Depersonalization following nitrazepam withdrawal". Biological Psychiatry. 31 (2): 212–3. doi:10.1016/0006-3223(92)90209-I. PMID 1737083. S2CID 26522217.
- ^ Grossman, Dave (1996). On Killing: The Psychological Cost of Learning to Kill in War and Society. Back Bay Books. ISBN 978-0-316-33000-8.
- ^ Reed, Graham (1972). The Psychology of Anomalous Experience. Hutchinson. p. 127. ISBN 9780091132408.
- ^ a b Cardeña, Etzel (1994). "The Domain of Dissociation". In Lynn, Steven J.; Rhue, Judith W. (eds.). Dissociation: Clinical and theoretical perspectives. New York: Guilford Press. pp. 15–31. ISBN 978-0-89862-186-0.
- ^ a b Sierra, Mauricio; Baker, Dawn; Medford, Nicholas; Lawrence, Emma; Patel, Maxine; Phillips, Mary L.; David, Anthony S. (2006). "Lamotrigine as an Add-on Treatment for Depersonalization Disorder". Clinical Neuropharmacology. 29 (5): 253–258. doi:10.1097/01.WNF.0000228368.17970.DA. PMID 16960469. S2CID 38595510.
- ^ Nuller, Yuri L.; Morozova, Marina G.; Kushnir, Olga N.; Hamper, Nikita (2001). "Effect of naloxone therapy on depersonalization: A pilot study". Journal of Psychopharmacology. 15 (2): 93–95. doi:10.1177/026988110101500205. PMID 11448093. S2CID 22934937.
- ^ Somer, Eli; Amos-Williams, Taryn; Stein, Dan J. (2013). "Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)". BMC Psychology. 1 (1): 20. doi:10.1186/2050-7283-1-20. PMC 4269982. PMID 25566370.
- ^ Medford, Nick; Sierra, Mauricio; Baker, Dawn; David, Anthony S. (2005). "Understanding and treating depersonalisation disorder". Advances in Psychiatric Treatment. 11 (2): 92–100. doi:10.1192/apt.11.2.92.
- ^ Depersonalisation Research Unit - Institute of Psychiatry, London
- ^ Jones, Zinnia (2017-06-29). "Depersonalization in gender dysphoria: widespread and widely unrecognized". Gender Analysis. Retrieved 2023-01-18.
- Loewenstein, Richard J; Frewen, Paul; Lewis-Fernández, Roberto (2017). "20 Dissociative Disorders". In Sadock, Virginia A; Sadock, Benjamin J; Ruiz, Pedro (eds.). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (10th ed.). Wolters Kluwer. ISBN 978-1-4511-0047-1.